Drug Topics this week ran a story that deserves more than a headline pass: how data is revolutionizing the pharmacist’s role in patient care. It isn’t a technology story. It is a clinical identity story, and it describes where the next generation of pharmacy leaders is being built right now.
The pharmacists winning in 2026 are not the ones filling the most prescriptions. They are the ones who can look at a patient’s data and tell a clinical story that nobody else in the room can tell.
The Context the ASHP Report Established
This newsletter covered the $1 trillion drug spending milestone two issues ago. The ASHP data contained a forward-looking directive most readers skimmed past.
ASHP forecasts heterogeneous institutional impact across the healthcare system, with cancer-, specialty-, and rare-disease-focused organizations experiencing disproportionate drug budget pressure. These organizations will see far higher drug-cost growth than those centered on routine care, making local utilization and contracting analytics essential for planning. The report specifically noted that organizations focused on cancer care, specialty medicine, and rare diseases will not be able to manage this cost environment without data-driven decision support at the pharmacy level.
The message from ASHP is explicit: general statements about drug spending trends won’t help a pharmacy director negotiate a formulary contract or a specialty pharmacist justify a new clinical service. Local data, analyzed by a pharmacist who understands what it means, is the competitive advantage.
The Three Competencies That Define the Data-Fluent Pharmacist in 2026
Medication Utilization Analytics
The most immediately actionable data skill for most pharmacists isn’t machine learning or bioinformatics. It is the ability to pull dispensing data, identify adherence gaps by condition, flag high-risk patients before they decompensate, and present those findings in a format that moves clinical and administrative decision-makers to act.
Poor medication adherence drives 33 to 69% of medication-related U.S. hospital admissions, at an estimated cost of $100 billion annually. Pharmacists who implement data analytics tools and patient stratification strategies specifically to address adherence produce outcomes that are directly measurable in hospital utilization and cost avoidance.
The pharmacist who produces a one-page quarterly summary showing adherence rates by condition, the number of care gap interventions completed, and the estimated hospitalizations avoided is not doing extra work. They are producing the evidence that justifies their own expanded role, clinical hire, or reimbursement negotiation. That document is the performance narrative that opens rooms that were previously closed.
Real-World Evidence Interpretation
The $1 trillion drug market is increasingly justified by real-world outcomes data rather than randomized controlled trial results alone. The Shields/UMass diabetes coaching study from PLOS ONE was real-world evidence. The ECO 2026 semaglutide menopausal data was real-world evidence. The biosimilar substitution results from the American Oncology Network were real-world evidence.
Real-world data now encompasses electronic health records, insurance claims, public health systems, wearable device outputs, and patient registries. The focus has shifted away from simply collecting large datasets toward securing high-quality, representative data that can be applied to specific clinical and commercial decisions. Organizations are increasingly interested in using real-world evidence to justify formulary decisions, demonstrate therapeutic value, and support payer negotiations.
Pharmacists who understand how to read, contextualize, and apply real-world evidence build the clinical arguments that move health systems and payers. This is not a research skill reserved for academic pharmacists. It is a practice skill that determines who gets invited to the contract negotiation table and who does not.
Population Health Dashboard Literacy
Healthcare Effectiveness Data and Information Set, known as HEDIS, is the most widely used performance improvement tool in American healthcare. HEDIS quality measures allow employers and consumers to compare the value of different health plans, identify opportunities to improve patient outcomes, and provide standard benchmarks for quality improvement initiatives. A large number of HEDIS measures center directly on disease states requiring medication management and optimization, including A1c control in diabetes, blood pressure targets, and medication adherence for statins, diabetes medications, and cardiovascular drugs.
CMS measures adherence to statin, blood pressure, and diabetes medications as part of its Medicare Part C and D Star ratings, representing 11% of the total ratings portfolio. These Star ratings affect a health plan’s profitability and a pharmacy organization’s value-based care incentives directly. Even though pharmacies aren’t scored for HEDIS or Star measures directly, they are incentivized through risk-based contracts and programs that reward improvement in these ratings.
The pharmacist who speaks Stars and HEDIS fluently is the one who gets called before payer contracts are finalized, not after. Pharmacist participation in value-based healthcare has been underutilized for too long, but this is changing. Pharmacist-led medication therapy management is a proven, cost-effective strategy for increasing patient knowledge and medication adherence, and MTM services address several key quality measures to reduce medication-related health risks and proactively engage patients in their care.
What This Looks Like in Practice: Real Job Descriptions, Real Requirements
The job market for pharmacists in 2026 confirms the skills gap in explicit terms.
Value-based care clinical pharmacist roles in 2026 now explicitly require the ability to use clinical, claims, and remote patient monitoring data to identify trends, gaps, and opportunities for improvement, develop and track outcome metrics related to medication optimization and adherence, identify performance gaps in Stars and HEDIS, and partner with clinical and network teams to design pharmacist-led interventions that improve quality metrics. Participation in payer quality meetings, program evaluations, and reporting cycles is expected as part of the role.
That job description would have described a senior pharmacy director five years ago. Today it describes an entry-level value-based care pharmacist in a growing number of organizations. The skills floor has risen. The pharmacists who began building these competencies early are the ones being offered those positions.
The Performance Narrative Gap Most Pharmacists Have
Here is the honest question this newsletter raised in the brief: if your pharmacy director or health system administrator asked you right now to summarize your clinical and financial impact last quarter in three data points, what would you say?
Most pharmacists don’t have an answer. Not because the impact doesn’t exist, but because it was never measured in a format anyone documented.
In Medicaid managed care, adherence performance functions as both a quality metric and an equity indicator. Adherence gaps are driven by structural constraints including instability in medication access, fragmented care coordination, inconsistent formulary alignment, and trust barriers. Pharmacist-led strategies, including structured risk stratification, targeted outreach, formulary optimization, and SDOH-integrated workflows, translate these disparities into measurable improvements, and those measurements are the foundation of any performance argument.
The gap is not clinical. It’s documentation. A pharmacist who performed 47 adherence interventions last quarter, resulting in 12 patients returning to therapeutic adherence for diabetes, can translate that directly into avoided hospitalizations using published cost models. A pharmacist who coordinated 8 biosimilar substitutions can calculate the cost savings per substitution and present a quarterly total. A pharmacist running GLP-1 adherence coaching can track A1c trends across the cohort and show improvement over two quarters.
None of these require a data science degree. They require a spreadsheet, a decision to start measuring, and the discipline to keep measuring.
Where to Start This Week
The pharmacist who has never tracked a clinical metric before should start with one, not five.
The highest-leverage starting metrics for most pharmacy settings are medication adherence rates for your top three chronic disease conditions, clinical intervention counts by category, and patient-level A1c or blood pressure improvements in your highest-risk cohorts.
Pick one. Define how you’ll measure it before the end of this week. Enter the first data point today. Return to it at the same time next week.
A physician-pharmacist team bringing a cohort of diabetes patients to an A1c goal of less than 7.0% did so in 99 fewer days than usual medical care by a physician alone. The pharmacist’s contribution to that outcome was measurable, documented, and directly attributable to clinical collaboration. That is the model: quantified pharmacist impact, linked to a specific patient outcome, documented in a format that clinical and administrative leadership can act on.
One number, tracked consistently, compounds into a compelling performance narrative within 90 days. That narrative is the currency of clinical credibility, the foundation of a billing expansion argument, and the evidence base that positions a pharmacist as an indispensable clinical partner rather than an interchangeable operational resource.
The pharmacists who build this capability in 2026 will lead their institutions. The ones who don’t will watch the capability requirement rise around them until the gap becomes a career problem.
Sources: Drug Topics (How Data Is Revolutionizing the Pharmacist’s Role in Patient Care, May 2026), ASHP / AJHP (National Trends in Prescription Drug Expenditures and Projections for 2026), PMC (Pharmacy Contributions to Improved Population Health), PMC (Impact of Pharmacist Participation in the Patient Care Team on Value-Based Health Measures), Outcomes.com (How Pharmacists Can Influence HEDIS Measures and Value-Based Care), GoAPHP (Managed Care Success: How Pharmacists Drive HEDIS and Stars, February 2026), Drug Store News (Achieving Medication Adherence: Creativity, Consultation, and Community), ZipRecruiter (Value-Based Care Clinical Pharmacist Job Posting, 2026), Pharmaceutical Technology (Emerging Trends in Real-World Data and AI’s Expanding Role, January 2026)